Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  ReNeuron Group plc    RENE   GB00BF5G6K95

RENEURON GROUP PLC

(RENE)
  Report
Delayed Quote. Delayed London Stock Exchange - 05/26 03:00:00 am
150 GBX   -0.66%
05/07RENEURON : CTX cell line shows further potential
PU
04/08RENEURON : Exosome Research Collaboration
AQ
04/06RENEURON : COVID-19 update
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

ReNeuron : Exosome Research Collaboration

share with twitter share with LinkedIn share with facebook
share via e-mail
04/08/2020 | 05:18am EDT

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces that it has signed a research agreement with an unnamed major pharmaceutical company to explore the potential use of the Company's proprietary exosomes to deliver novel therapeutics.

The agreement follows the Company's strategy of collaborating with pharmaceutical and biotechnology companies to use its exosome technology as a novel delivery vehicle. ReNeuron's exosomes are derived from its CTX neural stem cell line and have the ability to cross the blood brain barrier and to be manufactured at scale.

The research collaboration will focus on the use of the Company's exosomes for the delivery of gene silencing sequences created by the pharmaceutical company. ReNeuron will be responsible for manufacturing exosomes and then loading them with the gene silencing sequences after which the pharmaceutical company will evaluate the loaded exosomes. ReNeuron will be paid by the pharmaceutical company for manufacturing and loading the exosomes in the initial phase of the collaboration.

This is ReNeuron's second research collaboration following the signing of an ongoing agreement with a US pharmaceutical company in January 2019.

Commenting on the agreement, Olav Hellebo, Chief Executive Officer of ReNeuron, said: 'We are delighted to have signed this latest exosome research collaboration agreement with an experienced leader in the discovery and development of no vel gene silencing-based therapeutics. The collaboration is in line with our strategy of collaborating and then out-licensing our proprietary exosome technology as a novel delivery vector and underlines the potential commercial value of these proprietary nanoparticles generated from our CTX neural stem cell line.'

Contact:

Tel: +44 (0) 20 3819 8400

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered 'off-the-shelf' to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.

About ReNeuron's Exosome Platform

ReNeuron has established an endogenous, high-yielding, human neural stem cell (hNSC) derived exosome platform that can be produced through a fully qualified, xeno-free, optimised scalable GMP process. Conditional immortalisation of the cell-line ensures consistent exosome product.

ReNeuron's exosomes, being derived from neural stem cells, have a natural ability to cross the blood brain barrier.

The hNSC exosomes can loaded with siRNA/mRNA/miRNA, CRISPR/Cas9, antibodies, peptides, and small-molecules and engineered to target particular tissues.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as 'should', 'expects', 'estimates', 'believes' or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on RENEURON GROUP PLC
05/07RENEURON : CTX cell line shows further potential
PU
04/08RENEURON : Exosome Research Collaboration
AQ
04/06RENEURON : COVID-19 update
AQ
02/27CELL THERAPY : Challenges And Perspectives
AQ
02/25RENEURON : Positive long-term data in retinal clinical trial
AQ
01/09RENEURON : Corporate Presentation – January 2020
PU
2019RENEURON : Interim Results for the six months ended 30 September 2019
AQ
2019RENEURON : ReNeuron's lead cell line shows further potential
AQ
2019RENEURON : Positive clinical data presented at AAO meeting
AQ
2019RENEURON : AAO 2019 Presentation by Pravin Dugel MD
PU
More news
Financials (GBP)
Sales 2020 7,22 M
EBIT 2020 -19,4 M
Net income 2020 -16,0 M
Finance 2020 14,1 M
Yield 2020 -
P/E ratio 2020 -3,33x
P/E ratio 2021 -2,36x
EV / Sales2020 4,71x
EV / Sales2021 12,9x
Capitalization 48,1 M
Chart RENEURON GROUP PLC
Duration : Period :
ReNeuron Group plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RENEURON GROUP PLC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 497,05 GBp
Last Close Price 151,00 GBp
Spread / Highest target 357%
Spread / Average Target 229%
Spread / Lowest Target 101%
EPS Revisions
Managers
NameTitle
Olav Hellebø Chief Executive Officer & Executive Director
John Edward Berriman Non-Executive Chairman
Michael Elliot Hunt CFO, Secretary & Executive Director
John David Sinden Chief Scientific Officer
Richard L. Beckman Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
RENEURON GROUP PLC1.68%59
LONZA GROUP36.64%36 889
IQVIA HOLDINGS INC.-7.51%27 289
SEATTLE GENETICS, INC.36.33%26 964
MODERNA, INC.252.76%26 829
CELLTRION, INC.18.78%23 248